Document:

EX-10.2

 Exhibit 10.2 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE ZIOPHARM ONCOLOGY, INC. HAS
DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ZIOPHARM ONCOLOGY, INC. IF PUBLICLY DISCLOSED. 

AMENDMENT NO. 1 TO THE 

EXCLUSIVE LICENSE AGREEMENT 

THIS AMENDMENT NO. 1 TO THE EXCLUSIVE LICENSE AGREEMENT, (the “Amendment No. 1”) effective as of
October 15, 2020 (the “Effective Date of Amendment No. 1”), is made by and between Ziopharm Oncology, Inc., a Delaware corporation, with its principal place of business at One First Avenue, Parris
Building 34, Navy Yard Plaza, Boston, MA 02129 (“Ziopharm”), and PGEN Therapeutics, Inc. (formerly known as Precigen, Inc.), a Delaware corporation, with its principal place of business at 20358 Seneca Meadows
Parkway, Germantown, MD 20876 (“Precigen”). Ziopharm and Precigen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 

WHEREAS, Ziopharm and Precigen entered into the Exclusive License Agreement, dated as of October 5, 2018, (the
“Agreement”); 
 WHEREAS, Ziopharm and Precigen have a dispute regarding the delivery of certain information and materials
under the Agreement, and have agreed to settle this dispute by entering into this Amendment No. 1; and 
 WHEREAS, through this
Amendment No. 1, the Parties wish to compromise and fully and finally settle the above-referenced dispute, including all related matters in controversy and causes of action between them relating to the above-referenced dispute, without any
admission of liability. 
 NOW, THEREFORE, in consideration of the mutual covenants and promises of the Parties contained herein, the
sufficiency of which is hereby acknowledged, the Parties hereby agree as follows: 
 1.    Defined Terms. The
terms in this Amendment No. 1 with initial letters capitalized shall have the meanings set forth in this Amendment No. 1 and, if not defined in this Amendment No. 1, shall have the meaning set forth in the Agreement. 

2.    Immediate Transfers and Deliveries. A new Section 4.1(e) of the Agreement is hereby added to read as
follows: 
 “(e)    Immediate Transfers and Deliveries. Notwithstanding any other provision of the
Agreement, this Section 4.1(e) together with Section 4.1(f), set forth the Parties’ sole obligations and rights with respect to Precigen’s provision or transfer to Ziopharm of Licensed
Know-How relating to the IL-12 Program and Precigen’s inventory of IL-12 Products (including all final product, drug
substance, intermediates, works-in-process, formulation materials, reference 

 
standards, drug product clinical reserve samples, cell banks, viral banks, packaged retention samples, and the like): 

(i) Within [***] of the Effective Date of Amendment No. 1, Precigen will transfer and deliver to Ziopharm each of the items described on
Schedule 1 attached to Amendment No. 1. Precigen represents and warrants to Ziopharm that it has Control over, and the right to transfer and deliver, each of these items described on such Schedule 1 as contemplated hereby. 

(ii) Ziopharm may send follow-up notice(s) to Precigen to request additional items related to the
items on Schedule 1 (the “Additional Items”) within [***] from such transfer and delivery by Precigen to Ziopharm pursuant to Section 4.1(e)(i). Precigen will transfer and deliver the Additional Items to Ziopharm within [***]
of Ziopharm’s request; provided that (i) Ziopharm represents it cannot obtain the Additional Items without the participation of Precigen, and (ii) Precigen is in possession of and can reasonably locate the Additional Items.
Notwithstanding the prior sentence, Precigen may transfer and deliver such Additional Items to Ziopharm within sixty [***] of Ziopharm’s request provided that Precigen represents that production of the Additional Items within [***] would
materially interfere with Precigen’s (or the relevant individual or individuals’) ongoing business or other material obligations and commitments. Ziopharm shall reimburse Precigen for its out-of-pocket expenses and FTE costs incurred to perform the transfer provided solely under this Section 4.1(e)(ii) as set forth in Section 4.2, except that the applicable FTE rate shall be [***]
per hour. 
 (iii) Within [***] of the Effective Date of Amendment No. 1, Precigen shall prepare and send a letter to each vendor
listed on Schedule 2 attached to this Amendment No. 1 (each, “Vendor”) authorizing the Vendor to provide Ziopharm with information and documentation regarding work performed by the Vendor relating to the IL-12 Program prior to October 5, 2018, as identified by the batch/lot numbers or other specific identifying information specified on Schedule 2 (each, “Vendor Authorization Letter”). A model
Vendor Authorization Letter is attached as Schedule 3 to Amendment No. 1. In preparing the letter, Precigen will consider whether information concerning the identified batch/lot numbers contains information that is not related to the IL-12 Program (the “Unrelated Information”), in which case Precigen may add language to the letter instructing the Vendor to redact or otherwise withhold from Ziopharm such Unrelated Information.
Precigen will provide Ziopharm with a copy of each Vendor Authorization Letter, with redactions as determined by Precigen in its sole discretion. When requesting specific information from a Vendor pursuant to a Vendor Authorization Letter, Ziopharm
shall send Precigen via email a copy of the request at least [***] prior to sending the request to the Vendor, so that Precigen may consider whether and how Ziopharm’s request may implicate any Unrelated Information and provide further
instructions to the Vendor as appropriate. If despite Ziopharm’s good faith efforts to compile a comprehensive list in Schedule 2, Ziopharm later identifies additional relevant vendors and/or batch/lot numbers relating to the IL-12 Program prior to October 5, 2018, Precigen shall at Ziopharm’s request prepare and send additional Vendor Authorization Letters within [***] of such request. In the event Ziopharm discovers that
information it receives from a Vendor contains Unrelated Information, including but not limited to as a result of Precigen pointing out the existence of such information, Ziopharm shall immediately destroy all copies of such Unrelated Information
that are in Ziopharm’s possession or control and shall confirm to Precigen in writing that Ziopharm has destroyed all such copies. However, where a document contains both information relating to the IL-12
Program and Unrelated Information, Ziopharm shall be permitted to retain copies of the document provided that all Unrelated Information is redacted and inaccessible, and Ziopharm has confirmed to Precigen in writing that Ziopharm has redacted all
Unrelated Information. Ziopharm shall reimburse Precigen for its out-of-pocket expenses and FTE costs incurred in relation to the Vendor Authorization Letters under this
Section 4.1(e)(iii) as set forth in Section 4.2, except that the FTE rate shall be [***] per hour.” 

  
 -2- 

 (iv) For the avoidance of doubt, any items provided to Ziopharm by a Vendor pursuant to this
Amendment No. 1 shall be subject to the confidentiality provisions of the Agreement (including Article 10) as if the items were provided by Precigen directly. 

3.    Future IL-12 Transfers and Deliveries. A new Section 4.1(f) of
the Agreement is hereby added to read as follows: 
 “(f)    Future
IL-12 Transfers and Deliveries. For future requests, other than requests expressly authorized pursuant to Section 4.1(e)(ii), for Precigen’s provision or transfer to Ziopharm of Licensed Know-How relating to the IL-12 Program or any of Precigen’s inventory of IL-12 Products (including all final product, drug
substance, intermediates, works-in-process, formulation materials, reference standards, drug product clinical reserve samples, packaged retention samples, cell banks,
viral banks, and the like): 
 (i) Ziopharm’s first recourse for obtaining such items will be from the applicable Vendor through the
respective Vendor Authorization Letter. 
 (ii) Ziopharm may request such items from Precigen only if (x) the applicable Vendor does
not have or cannot provide the requested items to Ziopharm without further authorization from Precigen, (y) Ziopharm demonstrates a need for the requested items in connection with a request or requirement of a government regulator; and
(z) Ziopharm represents that it cannot obtain those items without the participation of Precigen. In the event Ziopharm satisfies each of these requirements, Precigen will produce such items to Ziopharm provided that Precigen is in Control of
and can reasonably locate the requested items. Precigen will produce any such items to Ziopharm within [***], except that Precigen may transfer and deliver such items to Ziopharm within [***] of Ziopharm’s request provided that Precigen
represents that production of the items within [***] would materially interfere with Precigen’s (or the relevant individual or individuals’) ongoing business or other material obligations and commitments. Ziopharm shall reimburse Precigen
for its out-of-pocket expenses and FTE costs incurred to perform the transfer provided solely under this Section 4.1(f) as set forth in Section 4.2, except
that the applicable FTE rate shall be [***] per hour. 
 (iii) Except as expressly set forth in Section 4.1(e) and 4.1(f), Precigen
shall have no obligations with respect to the provision or transfer to Ziopharm of any Licensed Know-How relating to the IL-12 Program or any of Precigen’s
inventory of IL-12 Products. For the avoidance of doubt, any items requested by Ziopharm pursuant to Section 4.1(e) and 4.1(f) must have been in existence at the time the Agreement was signed. For the
further avoidance of doubt, nothing herein shall require Precigen to disclose any confidential or proprietary information except insofar as such information relates to the IL-12 Program or IL-12 Products and otherwise meets the requirements of the Agreement as amended herein.” 

4.    Release. In consideration for the Parties agreeing to the terms of this Amendment No. 1, (a) Ziopharm,
on behalf of itself and its Affiliates, hereby releases and discharges Precigen and its respective subsidiaries, divisions, parents, Affiliates, agents and each of their respective officers, directors, employees, representatives and agents, and
(b) Precigen, on behalf of itself and its Affiliates, hereby releases and discharges Ziopharm and its subsidiaries, divisions, parents, 

  
 -3- 

 
Affiliates, agents and each of their respective officers, directors, employees, representatives and agents, in each foregoing case ((a) and (b)), from any and all Disputes existing as of the
Effective Date of this Amendment No. 1 concerning the Parties’ respective rights and obligations for the transfer or delivery of Licensed Know-How relating to the
IL-12 Program or IL-12 Products as provided for under Sections 4.1, 4.3 and 4.5 of the Agreement. 

5.    Amendment. This Amendment No. 1 shall not amend or modify the covenants, terms, conditions, rights and
obligations of the Parties under the Agreement, except as specifically set forth herein. The Agreement shall continue in full force and effect in accordance with its terms as amended by this Amendment No. 1. 

*    *    * 

IN WITNESS WHEREOF, the Parties have entered into this Amendment No. 1 in multiple counterparts as of the Effective Date of Amendment No. 1.

  

									
	Ziopharm Oncology, Inc.	 		 	PGEN Therapeutics, Inc.
					
	By:	 	 /s/ Laurence Cooper
	 		 	By:	 	 /s/ Donald Lehr

	Title:	 	CEO	 		 	Title:	 	Manager, Board of Managers

  
 -4- 

 Schedule 1 to Amendment No. 1 – Specified Transfers and Deliveries 

 

							
	 Item 

Number
	  	 Item
	  	 Location
	  	 Ziopharm Request

	 1
	  	[***]	  	[***]	  	[***]
	 2
	  	[***]	  	[***]	  	[***]
	 3
	  	[***]	  	[***]	  	[***]
	 4
	  	[***]	  	[***]	  	[***]
	 5
	  	[***]	  	[***]	  	[***]
	 6
	  	[***]	  	[***]	  	[***]
	 7
	  	[***]	  	[***]	  	[***]
	 8
	  	[***]	  	[***]	  	[***]
	 9
	  	[***]	  	[***]	  	[***]
	 10
	  	[***]	  	[***]	  	[***]
	 11
	  	[***]	  	[***]	  	[***]
	 12
	  	[***]	  	[***]	  	[***]
	 13
	  	[***]	  	[***]	  	[***]
	 14
	  	[***]	  	[***]	  	[***]
	 15
	  	[***]	  	[***]	  	[***]
	 16
	  	[***]	  	[***]	  	[***]
	 17
	  	[***]	  	[***]	  	[***]

  
 -5- 

 Schedule 2 to Amendment No. 1 – List of Vendors and Batch/Lot Numbers 

Veledimex & Maisine Formulated Veledimex: 
  

			
	 Vendor
	  	 Batches

	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

 Ad-RTS-hIL12 and Ad-RTS-mIL12: 
  

			
	 Vendor
	  	 Batches

	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

  
 -6- 

 Schedule 3 to Amendment No. 1 – Model Vendor Authorization Letter 

[Insert Date] 
 [Insert vendor name, address] 

Re: Release of data, information and records to Ziopharm 
 Dear
[Insert name], 
 [***] 
 Sincerely, 

PGEN Therapeutics, Inc. 
  

                          
                                   

[Name] 
 [Title] 

  
 -7-Document

Exhibit 10.1

Joinder Agreement No. 1

JOINDER AGREEMENT NO. 1, dated as of August 7, 2020 (this “Joinder”) to the SUPERPRIORITY SECURED DEBTOR IN POSSESSION CREDIT AGREEMENT, dated as of June 17, 2020 (the “Credit Agreement”), among INTELSAT JACKSON HOLDINGS S.A., a société anonyme existing under the laws of Luxembourg (the “Borrower”), the subsidiaries of the Borrower from time to time party thereto, as Guarantors (the “Guarantors”), the lending institutions from time to time parties thereto (each, a “Lender” and, collectively, the “Lenders”), Credit Suisse AG, Cayman Islands Branch, as the Administrative Agent and Collateral Agent and Credit Suisse Loan Funding LLC, as Lead Arranger. Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to such terms in the Credit Agreement.

WHEREAS, the Guarantors have entered into the Credit Agreement in order to induce the Administrative Agent, the Collateral Agent, the Lead Arranger and the Lenders to enter into the Credit Agreement and to induce the Lenders to make their respective Loans to the Borrower under the Credit Agreement. Section 9.11 of the Credit Agreement provides that additional Subsidiaries may become Guarantors under the Credit Agreement by execution and delivery of an instrument in the form of this Joinder. Each undersigned Subsidiary (each, a “New Guarantor”) is executing this Joinder in accordance with the requirements of the Credit Agreement to become a Guarantor under the Credit Agreement in order to induce the Lenders to make additional Loans and as consideration for Loans previously made.

Accordingly, the Administrative Agent and each New Guarantor agree as follows:

SECTION 1. In accordance with Section 9.11 of the Credit Agreement, each New Guarantor by its signature below hereby becomes a Guarantor under the Credit Agreement with the same force and effect as if originally named therein as a Guarantor, and each New Guarantor hereby (a) agrees to all the terms and provisions of the Credit Agreement applicable to it as a Guarantor thereunder and (b) represents and warrants that the representations and warranties made by it as a Guarantor thereunder are true and correct on and as of the date hereof. Each reference to a Guarantor in the Guarantee shall be deemed to include each New Guarantor. The Guarantee is hereby incorporated herein by reference.

SECTION 2. Each New Guarantor represents and warrants to the Administrative Agent and the other Guaranteed Parties that this Joinder has been duly authorized, executed and delivered by it and, subject to the Final DIP Order (if applicable to such New Guarantor), constitutes its legal, valid and binding obligation, enforceable against it in accordance with its terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or similar laws affecting creditors’ rights generally and subject to general principles of equity and subject to mandatory Luxembourg law provisions.

SECTION 3. This Joinder may be executed by one or more of the parties to this Joinder on any number of separate counterparts and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Any signature to this Joinder may be delivered by facsimile, electronic mail (including pdf) or any electronic signature complying with the U.S. federal ESIGN Act of 2000 or the New York Electronic Signature and Records Act 

or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes to the fullest extent permitted by applicable law. Each of the Parties represents and warrants to the other Parties that it has the corporate capacity and authority to execute this Joinder through electronic means.  A set of the copies of this Joinder signed by all the parties shall be lodged with the Borrower and the Administrative Agent. This Joinder shall become effective as to each New Guarantor when the Administrative Agent shall have received counterparts of this Joinder that, when taken together, bear the signatures of such New Guarantor and the Administrative Agent.

SECTION 4. Except as expressly supplemented hereby, the Credit Agreement shall remain in full force and effect.

SECTION 5. THIS JOINDER AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK AND, TO THE EXTENT APPLICABLE, THE BANKRUPTCY CODE.

SECTION 6. Any provision of this Joinder that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof and in the Credit Agreement, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. The parties hereto shall endeavor in good-faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions.

SECTION 7. All notices, requests and demands pursuant hereto shall be made in accordance with Section 14.2 of the Credit Agreement. All communications and notices hereunder to each New Guarantor shall be given to it in care of the Borrower at the Borrower’s address set forth in Section 14.2 of the Credit Agreement.

SECTION 8. Each New Guarantor agrees to reimburse the Administrative Agent for its out-of-pocket expenses in connection with this Joinder, including the fees, disbursements and other charges of counsel for the Administrative Agent.

IN WITNESS WHEREOF, each New Guarantor and the Administrative Agent have duly executed this Joinder to the Credit Agreement as of the day and year first above written.

Intelsat Velocity Holdings LLC,
as a New Guarantor

By: Intelsat Jackson Holdings S.A., its Sole
Member

By:      /s/ José Toscano                                   
            Name: José Toscano
Title:   Chairman & Chief Executive Officer

INTELSAT INVOICE SERVICES LLC,
as a New Guarantor

By: Intelsat Jackson Holdings S.A., its Managing
Member

By:      /s/ José Toscano                                   
            Name: José Toscano
Title:   Chairman & Chief Executive Officer

[Signature page to Joinder Agreement]

CREDIT SUISSE AG, CAYMAN ISLANDS
BRANCH, as Administrative Agent 

By:      /s/ William O’Daly                             
            Name: William O’Daly
            Title:    Authorized Signatory

By:      /s/ D. Andrew Maletta                         
            Name:  D. Andrew Maletta
            Title:    Authorized Signatory

[Signature page to Joinder Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]